Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dust mite sublingual immunotherapy in mono- versus dual-mite sensitized allergic rhinitis
ChiCTR2600131843Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of dermatophagoides farinae in allergic rhinitis (AR) (2 arms), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Change in Total Nasal Symptom Score (TNSS) at 12 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
dermatophagoides farinae
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on ChiCTR2600131843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131843.